Stifel Reiterates Buy Rating on Phathom (PHAT), PT $28, 'We leave our model unchanged, as our view reflected full 10-year exclusivity'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/15/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. HTFL
6. SNDK
7. DVLT
8. ADYYF
9. WDAY
10. ADYEN:NA

Go back to Stifel Reiterates Buy Rating on Phathom (PHAT), PT $28, 'We leave our model unchanged, as our view reflected full 10-year exclusivity'

Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets through May 3, 2032

June 6, 2025 12:27 PM EDT

FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathoms Citizen Petition filed on December 11, 2024 and communicated the Agencys intention to correct the Orange Book to recognize the proper 10 years of New Chemical Entity exclusivity for VOQUEZNA® (vonoprazan) tablets, extending through May 3, 2032.

About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a... More